There are few reports that conventional tumor immunotherapy shows a stable curative effect. The disappearance in the short term of the activated cytotoxic T-lymphocyte (CTL) clone administered to the patient and the inactivation of activated CTL in the cancerous part by regulatory T cells etc. are suggested to be the main causes. To overcome these problems, we planned a new clinical strategy to target the RNF43 peptide expressed abundantly in colon cancer, as the tumor-specific antigen. Based on our in vitro study results, we planned the following Phase I clinical protocol. First, we generate the activated CTL population which can react to the RNF43 peptide in vitro. Then, we use cyclophosphamide for the exclusion of regulatory T cells and administer RNF43 peptide pulse dendritic cells (DC) and interleukin-2 (IL-2) for maintenance and further activation of the activated CTL clone in vivo when we administer it.
|Number of pages||6|
|Publication status||Published - Sep 2008|
All Science Journal Classification (ASJC) codes
- Cancer Research